Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Russell 2000 Growth ETF (NQ:VTWG)

241.47 +2.30 (+0.96%)
Streaming Delayed Price Updated: 10:48 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Russell 2000 Growth ETF

This Wealth Firm Just Sold $8 Million in Small-Cap Stocks — Here’s Why
This Wealth Firm Just Sold $8 Million in Small-Cap Stocks — Here’s Why 
Via The Motley Fool
Topics ETFs Regulatory Compliance
BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial
BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. 
Via Stocktwits
DNUT Stock Trades Above 200-DMA For The First Time Since November 2024
Morgan Stanley kept its ‘Underweight’ rating and $2.5 price target on Krispy Kreme. 
Via Stocktwits
Topics ETFs
Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz
Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF. 
Via Stocktwits
Topics Artificial Intelligence ETFs
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer
Via Stocktwits
White House Reportedly Denies Plans To Acquire Stake In Critical Metals
Via Stocktwits
Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside
Via Stocktwits
Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder
Via Stocktwits
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment
SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. 
Via Stocktwits
Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer
Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 
Via Stocktwits
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year
Via Stocktwits
Krispy Kreme Stock Pops After FBI Director Kash Patel Reportedly Endorses It As A ‘Good Investment’: Retail Chatter Soars Over 600%
Via Stocktwits
Why Is aTyr Stock Falling Today?
Via Stocktwits
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
Via Stocktwits
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Via Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film
Via Stocktwits
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate
Via Stocktwits
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of... 
Via Stocktwits
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 
Via Stocktwits
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail
Via Stocktwits
X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target
The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right. 
Via Stocktwits
Topics Economy
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock
The company is now poised to initiate late-stage trials for Neflamapimod. 
Via Stocktwits
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.” 
Via Stocktwits
Topics Death
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and... 
Via Stocktwits
Vanguard Has 10 Different Small-Cap Exchange-Traded Funds (ETFs). Which Should You Buy Right Now?
You might be surprised at how many ways you can passively invest in small-cap stocks. 
Via The Motley Fool
Fabrinet Q2: Earnings Beat, Moderated Datacom Demand, Expanded Stock Buyback & More
FN shares down premarket after reporting Q2 results, beating revenue and EPS expectations. Company remains optimistic, authorizes $100M buyback. 
Via Benzinga
Topics Earnings
Prediction: This Will Be the Top-Performing Index ETF in 2025
Via The Motley Fool
Topics ETFs
The Best Vanguard Small-Cap ETFs to Invest $500 in Right Now
Via The Motley Fool
Topics ETFs
Prediction: These 5 High-Flying Vanguard ETFs Will Trounce the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.